- Home
- CABA vs GCGR Comparison
CABA vs GCGR Comparison
Compare CABA & GCGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CABA | GCGR |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.7M | 469.7M |
| IPO Year | 2019 | 2026 |
Fundamental Metrics
Financial Performance| Metric | CABA | GCGR |
|---|---|---|
| Price | $2.63 | $10.16 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $14.50 | N/A |
| AVG Volume (30 Days) | ★ 6.7M | 117.3K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.26 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.26 | $10.05 |
| 52 Week High | $4.23 | $10.20 |
Technical Indicators
Market Signals| Indicator | CABA | GCGR |
|---|---|---|
| Relative Strength Index (RSI) | 35.47 | 62.50 |
| Support Level | $2.11 | $10.09 |
| Resistance Level | $3.40 | N/A |
| Average True Range (ATR) | 0.23 | 0.04 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 4.72 | 66.67 |
Price Performance
Historical ComparisonAbout CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
About GCGR General Catalyst Global Resilience Merger Corp. Class A Ordinary Shares
General Catalyst Global Resilience Merger Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.